Predicting response to paclitaxel/carboplatin-based therapy in non-small cell lung cancer

Seminars in Oncology

Volumn 28, Issue 4 SUPPL. 14, 2001, Pages 37-44

  Rosell, Rafael ^a   Felip, Enriqueta ^a,b  

^a HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^b HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; BETA TUBULIN; CARBOPLATIN; CELL DNA; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE; EXCISION REPAIR CROSS COMPLEMENTING PROTEIN 1; GEFITINIB; GENE PRODUCT; GLYCOPROTEIN P; MESSENGER RNA; METALLOPROTEINASE INHIBITOR; METALLOTHIONEIN; NAVELBINE; PACLITAXEL; PROTEIN FARNESYLTRANSFERASE INHIBITOR; PROTEIN TYROSINE KINASE INHIBITOR; TENIPOSIDE; TRASTUZUMAB; UNCLASSIFIED DRUG; VASCULOTROPIN ANTIBODY;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CELL GROWTH; CELL PROLIFERATION; CLINICAL TRIAL; DNA DETERMINATION; DRUG ACTIVITY; DRUG EFFICACY; DRUG TOLERABILITY; EXCISION REPAIR; GENE MUTATION; GENE OVEREXPRESSION; HUMAN; LUNG NON SMALL CELL CANCER; PRIORITY JOURNAL; TREATMENT OUTCOME; TUMOR GROWTH;

EID: 0034786834     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/sonc.2001.27631     Document Type: Article

References (56)

1. Chemotherapy in non-small cell lung cancer: A meta-analysis using updated data on individual patients from 52 randomized clinical trials
2. Survival determinants in extensive-stage non-small-cell lung cancer: The Southwest Oncology Group experience
3. Taxol: A novel investigational antimicrotubule agent
4. Phase II study of Taxol, merbarone, and piroxantrone in stage IV non-small cell lung cancer. The Eastern Cooperative Oncology Group results
5. Phase II study of Taxol in patients with untreated advanced non-small cell lung cancer
6. Single-agent paclitaxel by 3-hour infusion in the treatment of non-small cell lung cancer: Links between p53 and K-ras gene status and chemosensitivity
7. Randomized trial of paclitaxel plus supportive care versus supportive care for patients with advanced non-small-cell lung cancer
8. Paclitaxel plus carboplatin in advanced non-small-cell lung cancer
9. Paclitaxel and carboplatin in combination in the treatment of advanced non-small-cell lung cancer: A phase II toxicity, response and survival analysis
10. Paclitaxel plus carboplatin in advanced non-small cell lung cancer: A phase II trial
11. Preliminary results of a phase I/II clinical trial of paclitaxel and carboplatin in non-small-cell lung cancer
12. Pharmacokinetics of paclitaxel and carboplatin in a dose-escalating and dose-sequencing study in patients with non-small-cell lung cancer
13. A phase I trial of paclitaxel plus carboplatin in untreated patients with advanced non-small cell lung cancer
14. 2) plus carboplatin in non-small cell lung cancer: A randomized study
15. Randomized study of paclitaxel-cisplatin versus cisplatin-teniposide in patients with advanced non-small cell lung cancer
16. Randomized phase III trial comparing cisplatin/etoposide versus carboplatin/paclitaxel in advanced and metastatic non-small cell lung cancer (NSCLC)
17. Comparison of survival and quality of life in advanced non-small-cell lung cancer patients treated with two dose levels of paclitaxel combined with cisplarin versus etoposide with cisplatin: Results of an Eastern Cooperative Oncology Group trial
18. Randomized phase III study of gemcitabine-cisplatin versus etopo-side-cisplatin in the treatment of locally advanced or metastatic non-small cell lung cancer
19. A randomized phase III trial of paclitaxel plus carboplatin (PC) versus vinorelbine plus cisplatin (VC) in untreated advanced non-small cell lung cancer (NSCLC): A Southwest Oncology Group (SWOG) trial
20. Randomized pan-European trial comparing paclitaxel (TAX)/carboplatin versus paclitaxel/cisplatin (CIS) in advanced non-small cell lung cancer (NSCLC)
21. A randomized phase III trial of four chemotherapy regimens in advanced non-small cell lung cancer (NSCLC)
22. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy
23. A randomized trial comparing perioperative chemotherapy and surgery with surgery alone in resectable stage IIIA non-small cell lung cancer
24. A randomized trial comparing preoperative chemotherapy plus surgery with surgery alone in patients with non-small-cell lung cancer
25. The integration of newer agents into neoadjuvant therapy
26. Stage III non-small cell lung cancer (NSCLC): Short course multimodality treatment with accelerated fractionation radiation, concurrent cisplatin/paclitaxel chemotherapy and surgery
27. Role of multimodality treatment for lung cancer
28. Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer
29. Phase III comparison of sequential vs concurrent chemoradiation for patients (pts) with unresected stage III non-small cell lung cancer (NSCLC): Initial report of Radiation Therapy Oncology Group (RTOG) 9410
30. Incorporation of paclitaxel and carboplatin in combined-modality therapy for locally advanced non-small cell lung cancer
31. Concurrent paclitaxel, carboplatin, and radiation therapy for locally advanced non-small cell lung cancer
32. Induction chemotherapy before surgery for early-stage lung cancer: A novel approach
33. Lung cancer epidemiology and genetics
34. From the bench to the bed: The need for translational research
35. Choosing anticancer drug targets in the postgenomic era
36. A randomized phase 11 trial comparing Rhumab VEGF (recombinant humanized monoclonal antibody to vascular endothelial cell growth factor) plus carboplatin/paclitaxel (CP) to CP alone in patients with stage IIIB/IV NSCLC
37. Paclitaxel (Taxol)
38. Taxol and other microtubule-interactive agents
39. Altered beta-tubulin isotype expression in paclitaxel-resistant human prostate carcinoma cells
40. Paclitaxel-resistant human ovarian cancer cells have mutant β-tubulins that exhibit impaired paclitaxel-driven polymerization
41. Taxol-resistant epithelial ovarian tumors are associated with altered expression of specific β-tubulin isotypes
42. Paclitaxel resistance in non-small cell lung cancer associated with beta-tubulin gene mutations
43. Antisense oligonucleotides to class III β-tubulin sensitize drug-resistant cells to Taxol
44. ERCC1 mRNA levels complement thymidylate synthase mRNA levels in predicting response and survival for gastric cancer patients receiving combination cisplatin and fluorouracil chemotherapy
45. Overexpression of metallothionein confers resistance to anticancer drugs
46. BRCA1 up-regulation is associated with repair-mediated resistance to cisdiamminedichloroplatinum (11)
47. Tumour site, sex, and survival in colorectal cancer
48. Colorectal tumors responding to 5-fluorouracil have low gene expression levels of dihydropyrimidine dehydrogenase, thymidylate synthase, and thymidine phosphorylase
49. Thymidylate synthase mRNA level in adenocarcinoma of the stomach: A predictor for primary tumor response and overall survival
50. Frequency and prognostic significance of isolated tumor cells in bone marrow of patients with non-small-cell lung cancer without overt metastases
51. Disseminated tumor cells in lymph nodes as a determinant for survival in surgically resected non-small-cell lung cancer
52. Free DNA in the serum of cancer patients and the effect of therapy
53. Detection and quantitation of circulating cancer cells in the peripheral blood of lung cancer patients
54. Detection of chromosome 3p alterations in serum DNA of non-small cell lung cancer patients
55. Detection of aberrant promoter hypermethylation of tumor suppressor genes in serum DNA from non-small cell lung cancer patients
56. Beta-tubulin mutations in circulating extracellular DNA of non-small-cell lung cancer (NSCLC) patients (pts)